Program
Biological Products
Also written as “Biological”, “AAV2-GDNF gene therapy” and “Biological/Vaccine: BNT162b2 10mcg”.
Its studies are mostly in Parkinson Disease · COVID-19 · Diabetes Mellitus, Type 1 · Carcinoma, Renal Cell · Metabolic Diseases, led by 11 companies.
Drug pageBiological Products: every studyMany companies study it; this page follows only the 12 they lead. All 27 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immune Cell | 22 open or running | phase 1since Dec 6, 2017 | Dec 6, 2017 | none ahead |
| Anchiano Therapeutics Israelits history only | 10 open or running | phase 2since Aug 8, 2011 | Aug 8, 2011 | none ahead |
| Bayerits history only | 11 open or running | phase 2since Feb 14, 2024 | Feb 14, 2024 | Aug 31, 2028phase 2 · NCT06285643 |
| BioNTechits history only | 10 open or running | phase 3since Mar 19, 2021 | Mar 19, 2021 | none ahead |
| DiaVacsits history only | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| GAIA BioMedicineits history only | 10 open or running | phase 2since Nov 19, 2021 | Nov 19, 2021 | none ahead |
| Lisata Therapeuticsits history only | 10 open or running | phase 1since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Longeveronits history only | 10 open or running | phase 2since Oct 23, 2015 | Oct 23, 2015 | none ahead |
| Sanofiits history only | 11 open or running | phase 1since Nov 24, 2025 | Nov 24, 2025 | none ahead |
| Sinopharmits history only | 10 open or running | phase 2since Jun 11, 2020 | Jun 11, 2020 | none ahead |
| Vertex Pharmaceuticalsits history only | 11 open or running | phase 3since Feb 13, 2025 | Feb 13, 2025 | none ahead |
Also a collaborator on its studies: Pfizer, Chengdu Institute of Biological Products and Simoon Record Pharma Information Consulting.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Immune Cell only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2017First studies: 2 phase 1 studiesFirst studyNCT03383965, NCT03383952
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Immune Cell leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03383965Hodgkin Disease · China | 1 | Recruiting | Dec 31, 2020 | 20 |
| NCT03383952Leukemia, B-Cell · China | 1 | Recruiting | Dec 31, 2020 | 20 |
How it is read
Names in the registry
- “Biological”, 2 entries
- “AAV2-GDNF gene therapy”, 1 entry
- “Biological/Vaccine: BNT162b2 10mcg”, 1 entry
- “Biological/Vaccine: BNT162b2 3mcg”, 1 entry
- “Biological/Vaccine: monovalent (hMPV) unlicensed comparator”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
- COVID-19, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Carcinoma, Renal Cell, 1 study
- Metabolic Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.